Roche Diagnostics To Expand Genomics Investments In Japan
This article was originally published in PharmAsia News
Executive Summary
At an interview with Yakuji News, Director of Applied Science of Tokyo-based Roche Diagnostics Japan Nobu Ogasawara said the company would be focusing investment on the rapidly growing genomics and cell engineering market. He estimated ¥10 billion ($92.8 million) revenue in five years. Last year Roche bought American companies Nimblegen Systems, 454 Lifesciences and Ventana, enhancing its products lineup in microarray, sequencer and RT-PCR area, and signed an exclusive licensing agreement on cell analytic technology with ACEA Bioscience. Ogasawara estimates new products will be launched in the second half of 2008. (Click for more-Japanese language